Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (181-190 of 274) with videos related to

Pageof 28
Sort By:
Blood|February 6, 2014
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk diseaseJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood Advances|December 5, 2023
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-upSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Plos One|June 27, 2019
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman diseaseChristopher S Nabel, Stephen Sameroff, Dustin Shilling, et al.
Blood Advances|August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell levelCarolina Schinke, Alexandra M Poos, Michael Bauer, et al.
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
Cancers|August 27, 2021
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple MyelomaLakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, et al.
Blood|August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Blood|May 7, 2015
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myelomaJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 28, 2017
Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple MyelomaMeera Mohan, Rohan S Samant, Donghoon Yoon, et al.
Blood|February 28, 2002
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan, Johanna Hardin, Bob Kordsmeier, et al.
Pageof 28

Showing results (181-190 of 274) with videos related to

Sort By:
Pageof 28
Blood|February 6, 2014
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk diseaseJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood Advances|December 5, 2023
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-upSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Plos One|June 27, 2019
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman diseaseChristopher S Nabel, Stephen Sameroff, Dustin Shilling, et al.
Blood Advances|August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell levelCarolina Schinke, Alexandra M Poos, Michael Bauer, et al.
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
Cancers|August 27, 2021
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple MyelomaLakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, et al.
Blood|August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Blood|May 7, 2015
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myelomaJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 28, 2017
Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple MyelomaMeera Mohan, Rohan S Samant, Donghoon Yoon, et al.
Blood|February 28, 2002
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan, Johanna Hardin, Bob Kordsmeier, et al.
Pageof 28